Lymphoma, T-Cell, Peripheral × Lenalidomide × Clear all Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
Phase 1 Completed
26 enrolled 24 charts
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Phase 1/2 Recruiting
250 enrolled
Lenalidomide and Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphomas
Phase 1/2 Terminated
12 enrolled
EpiBrentlen
Phase 1 Completed
6 enrolled
Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
Phase 1/2 Completed
58 enrolled 12 charts
PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma
Phase 4 Unknown
100 enrolled
Chidamide Combination With Lenalidomide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Phase 2 Unknown
44 enrolled
Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant
Phase 2 Terminated
3 enrolled 10 charts
Gemcitabine Hydrochloride, Rituximab, Oxaliplatin, and Lenalidomide in Treating Patients With Relapsed or Refractory, Aggressive Non-Hodgkin Lymphoma
Phase 2 Unknown
70 enrolled
Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Phase 1 Terminated
30 enrolled